Editor’s Letter

Latest features in GaBI Journal, 2017, Issue 3

Published in: Volume 6 / Year 2017 / Issue 3
Author(s):
Page: 103-4

It is clear that greater use of generics and biosimilars could greatly decrease healthcare costs and thereby increase availability of important medicines. It is equally clear that these potential savings… Read More »

Latest features in GaBI Journal, 2021, Issue 3

Published in: Volume 10 / Year 2021 / Issue 3
Author(s):
Page: 111-2

This issue of GaBI Journal contains articles dealing with some very practical issues related to the evaluation, describing, and use of generic and biosimilar products. These issues include the uncertainty… Read More »

What to look forward to in GaBI Journal, 2021, Issue 2

Published in: Volume 10 / Year 2021 / Issue 2
Author(s):
Page: 59-60

The current pandemic has greatly amplified the already existing disparities in access to health care. Many countries are facing a lack of access to or funding to pay for the… Read More »

First 2021 GaBI Journal issue highlights

Published in: Volume 10 / Year 2021 / Issue 1
Author(s):
Page: 3

The articles in this first issue contain a large volume of useful information on the global development, approval, manufacturing, marketing, and uptake of biosimilars. The first Original Research by Dr… Read More »

Medical journal publication during global stress

Published in: Volume 9 / Year 2020 / Issue 4
Author(s):
Page: 147-8

This issue of the GaBI Journal is being published during one of the most turbulent periods in over a century. A deadly pandemic is raging, the global economy is stressed,… Read More »

Latest features in GaBI Journal, 2020, Issue 3

Published in: Volume 9 / Year 2020 / Issue 3
Author(s):
Page: 95-6

The Commentary in this issue of the GaBI Journal by Dr Elwyn Griffiths discusses the need for more global harmonization of regulatory approaches to biological medicines. Dr Griffiths refers to… Read More »

What to look forward to in GaBI Journal, 2020, Issue 2

Published in: Volume 9 / Year 2020 / Issue 2
Author(s):
Page: 47-8

This issue of the GaBI Journal is being published as the global coronavirus 2 (SARS-CoV-2) pandemic is expanding rapidly in many areas of the world including in the United States… Read More »

Editor’s introduction to the initial issue of the ninth volume of GaBI Journal

Published in: Volume 9 / Year 2020 / Issue 1
Author(s):
Page: 3-4

The current coronavirus pandemic raises some important questions relevant to generic and/or biosimilar products. While still unproven, there are some indications that approved antiviral compounds exist which might be able… Read More »

Latest features in GaBI Journal, 2019, Issue 3

Published in: Volume 8 / Year 2019 / Issue 3
Author(s):
Page: 91-2

Patients, their families and providers are facing increasing pressures related to the rapidly expanding global inequality which affects access to all components of a long, healthy, productive life including water,… Read More »

Unmet potential of Generics and Biosimilars to reduce healthcare costs

Published in: Volume 8 / Year 2019 / Issue 2
Author(s):
Page: 47-8

The high cost of pharmaceuticals has been gaining increasing attention as a threat to both healthcare systems and patients’ access to care globally. This GaBI issue contains articles focusing on… Read More »

Page 1 of 4 1 2 3 4 Next »
Go Back Print